Benzinga | Nov 22, 2021 04:42AM EST

SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115

SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $112 to $115.